Provide feedbackProvide feedback

Home :: Urology

J&J returns Priligy product rights to Furiex

Tuesday, May 15 2012 | Comments
Evidence Grade 0 What's This?

Furiex Pharmaceuticals Inc. signed an agreement with Alza Corp. and Janssen Pharmaceutica NV, which are both Johnson & Johnson companies, that sets forth the terms under which Alza and Janssen will transfer the worldwide rights for Priligy (dapoxetine) to Furiex. Janssen has been marketing Priligy, which is a short-acting, selective serotonin reuptake inhibitor, as an on-demand treatment for premature ejaculation in 15 countries in Europe, Asia and Latin America. Altogether, the drug is...

Furiex Pharmaceuticals Inc. signed an agreement with Alza Corp. and Janssen Pharmaceutica NV, which are both Johnson & Johnson companies, that sets forth the terms under which Alza and Janssen will transfer the worldwide rights for Priligy (dapoxetine) to Furiex.

Janssen has been marketing Priligy, which is a short-acting, selective serotonin reuptake inhibitor, as an on-demand treatment for premature ejaculation in 15 countries in Europe, Asia and Latin America. Altogether, the drug is approved for that indication in 43 countries, although it is not approved in the United States.

Janssen will continue to manufacture and manage certain clinical and regulatory activities in connection with the product for a predefined period after the closing date of the agreement and will continue to make Priligy available to patients until the marketing authorization rights are transferred, at which time worldwide commercialization of the product will transition to Furiex or its licensee.

The transaction is expected to close in the third quarter.

Alza licensed dapoxetine from Pharmaceutical Product Development Inc. (PPD) in 2000. Furiex was spun off from PPD in 2010.

Latest News

Repros reaches agreement with FDA for registration program of investigational secondary hypogonadism treatment Verusmed

Thursday, May 10 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration and Repros Therapeutics Inc. agreed on the registration requirements for Androxal (enclomiphene citrate), an oral therapy Repros is developing as a treatment for secondary hypogonadism.

A key discussion point in the meeting between Repros and the regulatory agency was the overall required safety database. The FDA said that...



FDA lifts clinical hold on GTx's trials of Capesaris in advanced prostate cancer Verusmed

Tuesday, May 08 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration removed its full clinical hold on GTx Inc.'s Investigational New Drug (IND) application for Capesaris, a selective estrogen receptor alpha agonist that GTx is developing as a treatment for advanced prostate cancer.

The FDA issued the hold on clinical trials of the drug in February after GTx reported an...

Tags: Prostate Cancer, Prostate Cancer


Vivus' Stendra approved for ED Verusmed

Friday, April 27 2012 | Comments
Evidence Grade 0 What's This?

Vivus Inc. received approval from the Food and Drug Administration to market Stendra (avanafil) as a treatment for erectile dysfunction (ED).

Stendra, a highly selective phosphodiesterase type 5 inhibitor, is the first new prescription drug approved for ED in nearly a decade, Vivus noted.

The...



FDA rejects Amgen's Xgeva sBLA for prevention of bone metastases Verusmed

Friday, April 27 2012 | Comments
Evidence Grade 0 What's This?

Amgen Inc. received a complete response letter from the Food and Drug Administration regarding the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to treat men with castration-resistant prostate cancer who are at high risk for developing bone metastases. 

The FDA said it could not approve the application in its present form. According to...

Tags: Prostate Cancer, Prostate Cancer




  1. No articles have been read
  1. No articles have been emailed
Videos